Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Regeneus Ltd. ( (AU:CMB) ).
Cambium Bio Limited announced its quarterly cash flow report and business update, highlighting significant advancements including securing an R&D Tax Incentive approval for its Phase 3 program, which provides a 43.5% cash rebate on eligible clinical trial expenditures. The company also formed strategic partnerships with Keke Medtech, Benta SAS, and Locus Cell, validating the commercial potential of its human platelet lysate platform and enhancing its market positioning.
More about Regeneus Ltd.
Cambium Bio Limited is a clinical-stage regenerative medicine company that focuses on developing innovative biologics for ophthalmology and tissue repair applications.
Average Trading Volume: 19,220
Technical Sentiment Signal: Sell
Current Market Cap: A$11.02M
See more data about CMB stock on TipRanks’ Stock Analysis page.